LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,230
تعداد مقالات11,205
تعداد مشاهده مقاله78,022,976
تعداد دریافت فایل اصل مقاله103,587,262
Ekhtiyari, Mohammad Soleiman, Ghaderi-Zefrehei, Mostafa, Mogharari, Zahra, Yousefi, Maryam, Bigdeli, Ali, Nasre Esfahani, Effat, Shahriarpour, Hamed, Leschm, Bluma. (1404). Integrated Expression Analysis May Support Serine/Threonine Kinases as Common Hub Genes in Breast Cancer. سامانه مدیریت نشریات علمی, 50(10), 681-697. doi: 10.30476/ijms.2025.104386.3798
Mohammad Soleiman Ekhtiyari; Mostafa Ghaderi-Zefrehei; Zahra Mogharari; Maryam Yousefi; Ali Bigdeli; Effat Nasre Esfahani; Hamed Shahriarpour; Bluma J. Leschm. "Integrated Expression Analysis May Support Serine/Threonine Kinases as Common Hub Genes in Breast Cancer". سامانه مدیریت نشریات علمی, 50, 10, 1404, 681-697. doi: 10.30476/ijms.2025.104386.3798
Ekhtiyari, Mohammad Soleiman, Ghaderi-Zefrehei, Mostafa, Mogharari, Zahra, Yousefi, Maryam, Bigdeli, Ali, Nasre Esfahani, Effat, Shahriarpour, Hamed, Leschm, Bluma. (1404). 'Integrated Expression Analysis May Support Serine/Threonine Kinases as Common Hub Genes in Breast Cancer', سامانه مدیریت نشریات علمی, 50(10), pp. 681-697. doi: 10.30476/ijms.2025.104386.3798
Ekhtiyari, Mohammad Soleiman, Ghaderi-Zefrehei, Mostafa, Mogharari, Zahra, Yousefi, Maryam, Bigdeli, Ali, Nasre Esfahani, Effat, Shahriarpour, Hamed, Leschm, Bluma. Integrated Expression Analysis May Support Serine/Threonine Kinases as Common Hub Genes in Breast Cancer. سامانه مدیریت نشریات علمی, 1404; 50(10): 681-697. doi: 10.30476/ijms.2025.104386.3798

Integrated Expression Analysis May Support Serine/Threonine Kinases as Common Hub Genes in Breast Cancer

Iranian Journal of Medical Sciences
مقاله 4، دوره 50، شماره 10، دی 2025، صفحه 681-697    اصل مقاله (5.3 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2025.104386.3798
نویسندگان
Mohammad Soleiman Ekhtiyari1؛ Mostafa Ghaderi-Zefrehei* 2؛ Zahra Mogharari3؛ Maryam Yousefi4؛ Ali Bigdeli5؛ Effat Nasre Esfahani6؛ Hamed Shahriarpour5؛ Bluma J. Leschm7
1Division of Biochemistry, Faculty of Veterinary Medicine, University of Tabriz, Tabriz, Iran
2Department of Animal Genetics, Faculty of Agriculture, Yasouj University, Yasouj, Iran
3Department of Genetics, Faculty of Agriculture, Shahed University, Tehran, Iran
4Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
5Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
6Department of Animal Sciences, Payame Noor University, Tehran, Iran
7Department of Genetics, Department of Obstetrics, Gynecology and Reproductive Sciences, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA
چکیده
Background: Breast cancer (BC) is the most common cancer affecting women worldwide. There is a strong need to identify molecular pathways that might represent effective therapeutic targets. 
Methods: We conducted a large-scale transcriptomic analysis using publicly available datasets from the NCBI GEO and TCGA databases. Microarray datasets (GSE161533, GSE162228, GSE70947, and GSE139038) and RNA-Seq data were analyzed to identify differentially expressed genes (DEGs) using cut-off criteria of adjusted P<0.05 and |log2FC|>1. Gene co-expression networks were constructed using Weighted Gene co-expression Network Analysis (WGCNA) in R (version 1.68), followed by hub gene identification with STRING and MCODE tools. Functional enrichment was further explored through Gene Ontology analysis.
Results: Two regulatory modules enriched in cancer datasets were identified from both microarray and RNA-Seq analyses, corresponding to a network of 85 genes, compared to a distinct network of 474 genes enriched in control tissue samples. Further analyses to identify densely connected gene clusters within these networks revealed a cluster ``containing 29 cancer-related genes that included five hub gene candidates encoding serine/threonine kinase family proteins: NimA-Related Protein Kinase 2 (NEK2), Maternal Embryonic Leucine Zipper Kinase (MELK), Polo Like Kinase 1 (PLK1), Aurora Kinase B (AURKB), and Checkpoint Kinase 1 (CHEK1). Members of this family counter the expression of the tumor suppressor and cell cycle regulator Tumor Protein P53 (TP53), which is more highly expressed in healthy people. Moreover, all hub genes with higher transcript levels were associated with considerably poorer overall survival rates in BC patients. These results imply that these hub genes are relevant in terms of pathophysiology for the treatment of BC and deserve further attention. Kaplan-Meier survival analysis demonstrated that increased expression of all five genes was significantly associated with decreased survival (P<0.001). Hazard ratios (HRs) ranged from 1.41 to 1.77, indicating a substantial negative impact on patient survival for each gene.
Conclusion: Survival analysis showed that tumors with higher expression levels of hub genes were associated with significantly shorter overall survival times among breast cancer patients. This finding suggests that these hub genes are highly relevant to BC pathophysiology and could be considered targets for monitoring. 

تازه های تحقیق

Mohammad Soleiman Ekhtiyari (Google Scholar)

Mostafa Ghaderi-Zefrehei (Google Scholar)

کلیدواژه‌ها
Breast neoplasms (D001943)؛ Computational biology (D057180)؛ Molecular modeling (D052199)؛ Gene regulatory networks (D059687)؛ Neoplasm proteins (D009369)؛ Protein-serine-threonine kinases (D051685)؛ Mortality (D009020)
سایر فایل های مرتبط با مقاله
مراجع
  1. Coughlin SS. Epidemiology of Breast Cancer in Women. Adv Exp Med Biol. 2019;1152:9-29. doi: 10.1007/978-3-030-20301-6_2. PubMed PMID: 31456177.
  2. Le Blanc JM, Heller DR, Friedrich A, Lannin DR, Park TS. Association of Medicaid Expansion Under the Affordable Care Act With Breast Cancer Stage at Diagnosis. JAMA Surg. 2020;155:752-8. doi: 10.1001/jamasurg.2020.1495. PubMed PMID: 32609338; PubMed Central PMCID: PMCPMC7330827.
  3. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70. doi: 10.1038/nature11412. PubMed PMID: 23000897; PubMed Central PMCID: PMCPMC3465532.
  4. Koboldt D, Fulton R, McLellan M, Schmidt H, Kalicki-Veizer J, McMichael J, MD Anderson Cancer Center, et al. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:7418.
  5. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5:66. doi: 10.1038/s41572-019-0111-2. PubMed PMID: 31548545.
  6. DeBerardinis RJ. Tumor Microenvironment, Metabolism, and Immunotherapy. N Engl J Med. 2020;382:869-71. doi: 10.1056/NEJMcibr1914890. PubMed PMID: 32101671.
  7. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-33. doi: 10.1200/JCO.2006.09.1066. PubMed PMID: 17416853; PubMed Central PMCID: PMCPMC2267287.
  8. Antoniou AC, Cunningham AP, Peto J, Evans DG, Lalloo F, Narod SA, et al. The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer. 2008;98:1457-66. doi: 10.1038/sj.bjc.6604305. PubMed PMID: 18349832; PubMed Central PMCID: PMCPMC2361716.
  9. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-8. doi: 10.1056/NEJM199705153362001. PubMed PMID: 9145676.
  10. Breast Cancer Association C, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021;384:428-39. doi: 10.1056/NEJMoa1913948. PubMed PMID: 33471991; PubMed Central PMCID: PMCPMC7611105.
  11. Wilcox N, Dumont M, Gonzalez-Neira A, Carvalho S, Joly Beauparlant C, Crotti M, et al. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk. Nat Genet. 2023;55:1435-9. doi: 10.1038/s41588-023-01466-z. PubMed PMID: 37592023; PubMed Central PMCID: PMCPMC10484782.
  12. Shiovitz S, Korde LA. Genetics of breast cancer: a topic in evolution. Ann Oncol. 2015;26:1291-9. doi: 10.1093/annonc/mdv022. PubMed PMID: 25605744; PubMed Central PMCID: PMCPMC4478970.
  13. Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021;384:440-51. doi: 10.1056/NEJMoa2005936. PubMed PMID: 33471974; PubMed Central PMCID: PMCPMC8127622.
  14. Zhang D, Yang S, Li Y, Yao J, Ruan J, Zheng Y, et al. Prediction of Overall Survival Among Female Patients With Breast Cancer Using a Prognostic Signature Based on 8 DNA Repair-Related Genes. JAMA Netw Open. 2020;3:e2014622. doi: 10.1001/jamanetworkopen.2020.14622. PubMed PMID: 33017027; PubMed Central PMCID: PMCPMC7536586.
  15. Varn FS, Ung MH, Lou SK, Cheng C. Integrative analysis of survival-associated gene sets in breast cancer. BMC Med Genomics. 2015;8:11. doi: 10.1186/s12920-015-0086-0. PubMed PMID: 25881247; PubMed Central PMCID: PMCPMC4359519.
  16. Gyorffy B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 2021;19:4101-9. doi: 10.1016/j.csbj.2021.07.014. PubMed PMID: 34527184; PubMed Central PMCID: PMCPMC8339292.
  17. Aubrey BJ, Strasser A, Kelly GL. Tumor-Suppressor Functions of the TP53 Pathway. Cold Spring Harb Perspect Med. 2016;6. doi: 10.1101/cshperspect.a026062. PubMed PMID: 27141080; PubMed Central PMCID: PMCPMC4852799.
  18. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 2006;34:1416-26. doi: 10.1093/nar/gkl010. PubMed PMID: 16522651; PubMed Central PMCID: PMCPMC1390683.
  19. Bansal I, Pandey AK, Ruwali M. Small-molecule inhibitors of kinases in breast cancer therapy: recent advances, opportunities, and challenges. Front Pharmacol. 2023;14:1244597. doi: 10.3389/fphar.2023.1244597. PubMed PMID: 37711177; PubMed Central PMCID: PMCPMC10498465.
  20. Cioffi A, De Cobelli O, Veronesi P, La Vecchia C, Maisonneuve P, Corso G. Prevalence of Germline BRCA1/2 Variants in Ashkenazi and Non-Ashkenazi Prostate Cancer Populations: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023;15. doi: 10.3390/cancers15010306. PubMed PMID: 36612302; PubMed Central PMCID: PMCPMC9818251.
  21. Springer T. The Role of Reproductive Risk Factors in Hereditary Breast Cancer Within BRCA Mutation Carriers: Systematic Review and Meta-Analysis. Washington: Georgetown University; 2021.
  22. Moller NB, Boonen DS, Feldner ES, Hao Q, Larsen M, Laenkholm AV, et al. Validation of the BOADICEA model for predicting the likelihood of carrying pathogenic variants in eight breast and ovarian cancer susceptibility genes. Sci Rep. 2023;13:8536. doi: 10.1038/s41598-023-35755-8. PubMed PMID: 37237042; PubMed Central PMCID: PMCPMC10220031.
  23. Xie Y, Shi H, Han B. Bioinformatic analysis of underlying mechanisms of Kawasaki disease via Weighted Gene Correlation Network Analysis (WGCNA) and the Least Absolute Shrinkage and Selection Operator method (LASSO) regression model. BMC Pediatr. 2023;23:90. doi: 10.1186/s12887-023-03896-4. PubMed PMID: 36829193; PubMed Central PMCID: PMCPMC9951419.
  24. Asparuhova MB, Riedwyl D, Aizawa R, Raabe C, Couso-Queiruga E, Chappuis V. Local Concentrations of TGF-beta1 and IGF-1 Appear Determinant in Regulating Bone Regeneration in Human Postextraction Tooth Sockets. Int J Mol Sci. 2023;24. doi: 10.3390/ijms24098239. PubMed PMID: 37175951; PubMed Central PMCID: PMCPMC10179638.
  25. Wei E, Hu M, Wu L, Pan X, Zhu Q, Liu H, et al. TGF-beta signaling regulates differentiation of MSCs in bone metabolism: disputes among viewpoints. Stem Cell Res Ther. 2024;15:156. doi: 10.1186/s13287-024-03761-w. PubMed PMID: 38816830; PubMed Central PMCID: PMCPMC11140988.
  26. Sheynkman GM, Shortreed MR, Frey BL, Scalf M, Smith LM. Large-scale mass spectrometric detection of variant peptides resulting from nonsynonymous nucleotide differences. J Proteome Res. 2014;13:228-40. doi: 10.1021/pr4009207. PubMed PMID: 24175627; PubMed Central PMCID: PMCPMC3947302.
  27. Qiu H, Li R, Li P, Xing W [Internet]. Expression data from esophageal squamous cell carcinoma patients. [cited 17 November 2020]. Available from: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE161533
  28. Chen YJ, Huang CS, Phan NN, Lu TP, Liu CY, Huang CJ, et al. Molecular subtyping of breast cancer intrinsic taxonomy with oligonucleotide microarray and NanoString nCounter. Biosci Rep. 2021;41. doi: 10.1042/BSR20211428. PubMed PMID: 34387660; PubMed Central PMCID: PMCPMC8385191.
  29. Quigley DA, Tahiri A, Lüders T, Riis MH, Balmain A, Børresen-Dale A-L, et al. Abstract B59: Age and estrogen-dependent inflammation in breast adenocarcinoma and normal breast tissue. Molecular Cancer Research. 2016;14:B59-B.
  30. Rajkumar T, Amritha S, Sridevi V, Gopal G, Sabitha K, Shirley S, et al. Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women. Sci Rep. 2022;12:100. doi: 10.1038/s41598-021-04176-w. PubMed PMID: 34997107; PubMed Central PMCID: PMCPMC8742108.
  31. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284-7. doi: 10.1089/omi.2011.0118. PubMed PMID: 22455463; PubMed Central PMCID: PMCPMC3339379.
  32. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559. doi: 10.1186/1471-2105-9-559. PubMed PMID: 19114008; PubMed Central PMCID: PMCPMC2631488.
  33. Bawono P, Heringa J. PRALINE: a versatile multiple sequence alignment toolkit. Methods Mol Biol. 2014;1079:245-62. doi: 10.1007/978-1-62703-646-7_16. PubMed PMID: 24170407.
  34. Krieger E, Vriend G. YASARA View - molecular graphics for all devices - from smartphones to workstations. Bioinformatics. 2014;30:2981-2. doi: 10.1093/bioinformatics/btu426. PubMed PMID: 24996895; PubMed Central PMCID: PMCPMC4184264.
  35. Oshi M, Gandhi S, Huyser MR, Tokumaru Y, Yan L, Yamada A, et al. MELK expression in breast cancer is associated with infiltration of immune cell and pathological compete response (pCR) after neoadjuvant chemotherapy. Am J Cancer Res. 2021;11:4421-37. PubMed PMID: 34659896; PubMed Central PMCID: PMCPMC8493385.
  36. Huang X, Zhang G, Tang T, Gao X, Liang T. One shoot, three birds: Targeting NEK2 orchestrates chemoradiotherapy, targeted therapy, and immunotherapy in cancer treatment. Biochim Biophys Acta Rev Cancer. 2022;1877:188696. doi: 10.1016/j.bbcan.2022.188696. PubMed PMID: 35157980.
  37. Zhang X, Huang X, Xu J, Li E, Lao M, Tang T, et al. NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1. Nat Commun. 2021;12:4536. doi: 10.1038/s41467-021-24769-3. PubMed PMID: 34315872; PubMed Central PMCID: PMCPMC8316469.
  38. Liu Z, Sun Q, Wang X. PLK1, A Potential Target for Cancer Therapy. Transl Oncol. 2017;10:22-32. doi: 10.1016/j.tranon.2016.10.003. PubMed PMID: 27888710; PubMed Central PMCID: PMCPMC5124362.
  39. Equilibrina I, Krayukhina E, Inoue K, Ishikawa Y, Kawamoto A, Kato T, et al. The role of phosphorylation of histone H3 at serine 10 in chromatin condensation in vitro. Chromosome Science. 2015;18:9-14.
  40. Wu M, Pang JS, Sun Q, Huang Y, Hou JY, Chen G, et al. The clinical significance of CHEK1 in breast cancer: a high-throughput data analysis and immunohistochemical study. Int J Clin Exp Pathol. 2019;12:1-20. PubMed PMID: 31933717; PubMed Central PMCID: PMCPMC6944032.
  41. Bhullar KS, Lagaron NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer. 2018;17:48. doi: 10.1186/s12943-018-0804-2. PubMed PMID: 29455673; PubMed Central PMCID: PMCPMC5817855.
  42. Ghafouri-Fard S, Khoshbakht T, Hussen BM, Dong P, Gassler N, Taheri M, et al. A review on the role of cyclin dependent kinases in cancers. Cancer Cell Int. 2022;22:325. doi: 10.1186/s12935-022-02747-z. PubMed PMID: 36266723; PubMed Central PMCID: PMCPMC9583502.
  43. Aquino-Acevedo AN, Orengo-Orengo JA, Cruz-Robles ME, Saavedra HI. Mitotic kinases are emerging therapeutic targets against metastatic breast cancer. Cell Div. 2024;19:21. doi: 10.1186/s13008-024-00125-x. PubMed PMID: 38886738; PubMed Central PMCID: PMCPMC11184769.
آمار
تعداد مشاهده مقاله: 1,692
تعداد دریافت فایل اصل مقاله: 294


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب